The first patient has been treated with InterVene’s Recana thrombectomy system for restoring patency (blood flow) in chronically obstructed deep veins and venous stents.

Each year in the UK, 30,000 children under the age of five are hospitalised with RSV and it causes around 30 infant deaths.

Sarepta CEO Doug Ingram said it is important the company maintains a “positive working relationship” with the FDA.

New guidelines recommended by WHO will need to be backed with funding to be implemented at scale in affected communities.

Monte Rosa Therapeutics has dosed the first participants in the Phase I trial of the NEK7-directed molecular glue degrader (MGD), MRT-8102.

Walgreens is not the only company in the US that has tried to expand beyond standard pharmacy operations. For example, CVS had tried to assist with clinical trials but closed the facility down after ...

AstraZeneca's Tagrisso combined with pemetrexed and platinum-based chemotherapy has shown improvement in overall survival (OS).

Sarepta Therapeutics is refusing to pull its gene therapy Elevidys (delandistrogene moxeparvovec), despite a request from the FDA.

Bristol Myers Squibb (BMS) has revealed that its Phase III trial assessing Reblozyl with JAKi therapy did not meet its primary goal.

Industry experts have provided insight into how oncology clinical trials can be designed for success from the outset and rendered as patient-centric as possible.

Viatris’ investigational blepharitis ointment failed to achieve the primary endpoint in its Phase III trial, prompting the company to reconsider the drug’s future. The Phase III study (NCT06400511) ...